SMTL ID : 7r0q.2 (1 other biounit)

KRasG12C in complex with GDP and compound 3

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.95 Å

Oligo State

monomer

Ligands

1 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 2 residues within 4Å: Chain A: S.18 Ligands: GDP.3 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:S.18, H2O.1, H2O.1, H2O.1, H2O.2

1 x H0O: ~{N}-[4-[3,5-dimethyl-4-(5-methyl-2~{H}-indazol-4-yl)pyrazol-1-yl]phenyl]propanamide(Covalent)

H0O.2: 18 residues within 4Å: Chain A: G.11, C.13, K.17, P.35, A.60, G.61, Q.62, E.63, E.64, S.66, R.69, D.70, M.73, H.96, Y.97, Q.100, R.103, V.104 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:R.69, A:Y.97, A:Q.100, A:Q.100, A:V.104 Hydrogen bonds: A:K.17, A:G.61, A:S.66, A:S.66, A:R.103 pi-Stacking: A:Y.97

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.3: 20 residues within 4Å: Chain A: A.12, C.13, G.14, V.15, G.16, K.17, S.18, A.19, F.29, V.30, D.31, Y.33, N.117, K.118, D.120, L.121, S.146, A.147, K.148 Ligands: MG.1 23 PLIP interactions: 23 interactions with chain A Hydrogen bonds: A:G.14, A:V.15, A:G.16, A:K.17, A:S.18, A:A.19, A:V.30, A:D.31, A:Y.33, A:N.117, A:K.118, A:K.118, A:A.147, A:K.148, A:K.148 Water bridges: A:S.18, A:S.18, A:S.18, A:Y.33 Salt bridges: A:K.17, A:D.120 pi-Stacking: A:F.29, A:F.29

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Weiss, A. et al., Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov (2022)

Release Date

2022-04-27

Peptides

GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

GTPase KRas

Related Entries With Identical Sequence